ArticleScientific reports2025
Aggregate index of systemic inflammation as a new prognostic marker in patients with coronary artery disease undergoing PCI.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic value of the aggregate index of systemic inflammation in predicting in-hospital adverse outcomes among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.BMC cardiovascular disorders · 2026Article
- Article
- Association Between the Aggregate Index of Systemic Inflammation (AISI) and Tirofiban Use During Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This article aim is to assess the association between the aggregate index of systemic inflammation (AISI) and long-term outcomes of coronary artery disease (CAD) patients after percutaneous coronary intervention (PCI). 3482 patients are divided into the higher group (AISI ≥ 366) and the lower group (AISI < 366) according to cut-off value of AISI. The mean follow-up time was 37.59 ± 22.24 months. The primary endpoint includes all-cause mortality (ACM) and cardiac mortality (CM) and secondary endpoints include major adverse cardiovascular events (MACEs) and major adverse cardiovascular and cerebrovascular events (MACCEs). The results show that there are statistically significant differences in primary endpoint incidence. The incidence of ACM is 6.6% in higher group and 2.6% in lower group (P < 0.001) while the incidence of CM is 4.1% in higher group and 1.7% in lower group (P < 0.001). Cox regression analysis shows that the risk of ACM was increased to 2.298 times (HR = 2.298, 95% CI: 1.595-3.310, P < 0.001) and the risk of CM was increased to 2.160 times (HR = 2.160, 95% CI: 1.358-3.436, P = 0.001) in the higher group. Therefore, AISI is an independent predictor for CAD patients after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.